Odyssey Therapeutics initiated at Outperform by Raymond James
Raymond James initiated coverage of Odyssey Therapeutics with an Outperform rating, according to a Benzinga-reported ratings action.
Story updates
11:12:10 AM UTC
SquawkNews
Odyssey Therapeutics Price Target Announced at $42.00/Share by Raymond James